Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | CCKAR | P32238 | 4/20 | 0.50 |
| ▸ | CCKBR | P32239 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15230991 | 1.00 | GLP1R (0.58) | GLP1RFAAHITGB3ITGA2BCCKAR | |
| SCHEMBL15231176 | 1.00 | GLP1R (0.58) | GLP1RFAAHITGB3ITGA2BCCKAR | |
| SCHEMBL15232065 | 0.91 | GLP1R (0.64) | GLP1RCCKARCCKBR | |
| SCHEMBL15232216 | 0.91 | GLP1R (0.64) | GLP1RCCKARCCKBR | |
| SCHEMBL15232062 | 0.91 | GLP1R (0.64) | GLP1RCCKARCCKBR | |
| SCHEMBL15360200 | 0.85 | GLP1R (0.69) | GLP1RCCKARCCKBR | |
| SCHEMBL15359923 | 0.85 | GLP1R (0.69) | GLP1RCCKARCCKBR | |
| SCHEMBL327205 | 0.84 | FAAH (0.58) | FAAHITGB3ITGA2B | |
| SCHEMBL22085201 | 0.83 | GLP1R (0.62) | GLP1R | |
| SCHEMBL24225996 | 0.82 | GLP1R (0.65) | GLP1RCCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038435-A1 | N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | disclosed |
| EP-2820150-A1 | N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF | Novo Nordisk A/S (DK) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013128003-A1 | N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2013-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038435-A1 | N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF | NGLY1, PTMS, VIP | GLP1R 58/4885FAAH 398/4885ITGB3 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.